Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,486,683 shares of the company’s stock after selling 876,000 shares during the period. Teva Pharmaceutical Industries accounts for approximately 4.8% of Clal Insurance Enterprises Holdings Ltd’s investment portfolio, making the stock its 4th biggest position. Clal Insurance Enterprises Holdings Ltd owned approximately 2.75% of Teva Pharmaceutical Industries worth $633,456,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Phoenix Financial Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after buying an additional 3,533,800 shares during the last quarter. National Pension Service grew its position in Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after acquiring an additional 404,526 shares during the last quarter. Oak Harvest Investment Services acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $1,010,000. Public Sector Pension Investment Board increased its holdings in Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $33.85 on Friday. The business has a 50-day moving average price of $32.94 and a two-hundred day moving average price of $25.68. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The company has a market cap of $38.92 billion, a P/E ratio of 28.21, a PEG ratio of 11.30 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 422,060 shares of company stock worth $12,254,965. 0.49% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Scotiabank boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Finally, Truist Financial increased their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.